Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Hoffmann

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
International Journal of Stroke : Official Journal of the International Stroke Society|August 29, 2012
STRoke Adverse outcome is associated WIth NoSocomial Infections (STRAWINSKI): procalcitonin ultrasensitive-guided antibacterial therapy in severe ischaemic stroke patients - rationale and protocol for a randomized controlled trialLena Ulm, Stephanie Ohlraun, Hendrik Harms, et al.
Molecular Pharmacology|August 24, 2007
Dimerization region of soluble guanylate cyclase characterized by bimolecular fluorescence complementation in vivoChristiane Rothkegel, Peter M Schmidt, Derek-John Atkins, et al.
European Journal of Neurology|January 31, 2022
Daratumumab for treatment-refractory antibody-mediated diseases in neurologyFranziska Scheibe, Lennard Ostendorf, Harald Prüss, et al.
European Journal of Neurology|November 14, 2025
AXIN1, STAMBP, ST1A1, CDCP1, and SIRT2 Validated as Myasthenia Gravis Biomarkers: A Comparative Proteomic Study With MS, CIDP, and ControlsAmol K Bhandage, Sarah Hoffmann, Carla Dusemund, et al.
Frontiers in Neurology|January 1, 2024
The burden of myasthenia gravis - highlighting the impact on family planning and the role of social supportMaike Stein, Ulrike Grittner, Regina Stegherr, et al.
Archives of Gynecology and Obstetrics|March 16, 2024
Pregnancy in myasthenia gravis: a retrospective analysis of maternal and neonatal outcome from a large tertiary care centre in GermanyJakob Draxler, Andreas Meisel, Frauke Stascheit, et al.
Journal of Medical Ethics|May 7, 2020
Withholding or withdrawing life support in long-term neurointensive care patients: a single-centre, prospective, observational pilot studyMaria-Ioanna Stefanou, Mihaly Sulyok, Martin Koehnlein, et al.
Journal of Hypertension|July 9, 2010
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin modelsYuliya Sharkovska, Philipp Kalk, Bettina Lawrenz, et al.
Journal of Neurology|June 13, 2024
Fatigue and associated factors in myasthenia gravis: a nationwide registry studyMattea Funke, Maria Eveslage, Jana Zschüntzsch, et al.
Journal of Neurology|June 3, 2026
Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT)James F Howard, Francesco Saccà, Sarah Hoffmann, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
International Journal of Stroke : Official Journal of the International Stroke Society|August 29, 2012
STRoke Adverse outcome is associated WIth NoSocomial Infections (STRAWINSKI): procalcitonin ultrasensitive-guided antibacterial therapy in severe ischaemic stroke patients - rationale and protocol for a randomized controlled trialLena Ulm, Stephanie Ohlraun, Hendrik Harms, et al.
Molecular Pharmacology|August 24, 2007
Dimerization region of soluble guanylate cyclase characterized by bimolecular fluorescence complementation in vivoChristiane Rothkegel, Peter M Schmidt, Derek-John Atkins, et al.
European Journal of Neurology|January 31, 2022
Daratumumab for treatment-refractory antibody-mediated diseases in neurologyFranziska Scheibe, Lennard Ostendorf, Harald Prüss, et al.
European Journal of Neurology|November 14, 2025
AXIN1, STAMBP, ST1A1, CDCP1, and SIRT2 Validated as Myasthenia Gravis Biomarkers: A Comparative Proteomic Study With MS, CIDP, and ControlsAmol K Bhandage, Sarah Hoffmann, Carla Dusemund, et al.
Frontiers in Neurology|January 1, 2024
The burden of myasthenia gravis - highlighting the impact on family planning and the role of social supportMaike Stein, Ulrike Grittner, Regina Stegherr, et al.
Archives of Gynecology and Obstetrics|March 16, 2024
Pregnancy in myasthenia gravis: a retrospective analysis of maternal and neonatal outcome from a large tertiary care centre in GermanyJakob Draxler, Andreas Meisel, Frauke Stascheit, et al.
Journal of Medical Ethics|May 7, 2020
Withholding or withdrawing life support in long-term neurointensive care patients: a single-centre, prospective, observational pilot studyMaria-Ioanna Stefanou, Mihaly Sulyok, Martin Koehnlein, et al.
Journal of Hypertension|July 9, 2010
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin modelsYuliya Sharkovska, Philipp Kalk, Bettina Lawrenz, et al.
Journal of Neurology|June 13, 2024
Fatigue and associated factors in myasthenia gravis: a nationwide registry studyMattea Funke, Maria Eveslage, Jana Zschüntzsch, et al.
Journal of Neurology|June 3, 2026
Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT)James F Howard, Francesco Saccà, Sarah Hoffmann, et al.
Pageof 9